Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

ed in mouse models that treatment of hormone resistant human prostate cancer with intravenous PEGPH20 in combination with the chemotherapeutic drugs docetaxel (Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a substantial increase in anti-tumor activity. The docetaxel plus PEGPH20 combination treatment demonstrated significantly enhanced survival compared to treatment with docetaxel alone. These results and other findings support initiation of a Phase 1, dose escalation, intravenous, PEGPH20 monotherapy trial that is expected to begin during the first half of 2009 in late stage, refractory cancer patients.

-- Baxter announced it submitted an IND to the FDA to conduct a Phase 3 clinical trial with GAMMAGARD LIQUID plus Halozyme's Enhanze(TM) Technology as a subcutaneous injection via a single site for the treatment of primary immune deficiency.

Third Quarter 2008 Financial Results

-- Net loss for the third quarter of 2008 was $10.9 million, or $0.14 per share, compared with a net loss for the third quarter of 2007 of $7.0 million, or $0.09 per share. Net loss for the nine months ended September 30, 2008 was $31.8 million, or $0.40 per share, compared with a net loss of $15.2 million, or $0.21 per share, for the comparable period last year.

-- Revenues for the third quarter of 2008 were $2.5 million, compared with $943,000 for the third quarter of 2007. Revenues under collaborative agreements for the third quarter of 2008 were $2.2 million, compared with $758,000 for the third quarter of 2007. Revenues under collaborative agreements in the third quarter of 2008 primarily consisted of the amortization of upfront fees received from Baxter and Roche of $588,000 and research and development reimbursements from Baxter of $847,000 and Roche of $760,000. Revenues under collaborative agreements for the third quarter of 2007 primarily consisted of the amortization of upfront fees received from Baxter and Roche of $477,000 and research a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Md., May 5, 2011 GenVec, Inc. (NASDAQ: GNVCD) today ... letter from The NASDAQ Stock Market ("NASDAQ") advising that it ... GenVec had received a notice of deficiency on ... compliance with NASDAQ Marketplace Rules because the bid price of ...
... Reportlinker.com announces that a new market research report ... Tumor Markers - Global Pipeline Analysis, Competitive Landscape ... http://www.reportlinker.com/p0490349/Tumor-Markers---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html Tumor Markers - ... to 2017 Summary ...
... 4, 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... material, today announced that its chairman and CEO, Guy Cook, ... Equity Conference at the Hard Rock Hotel in Hollywood, Florida, ... At the time of the presentation, a live audio ...
Cached Biology Technology:GenVec Regains Compliance with NASDAQ Listing Requirements 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:7/10/2014)... are a big, bad sea scorpion. , One minute, ... any prey in sight. The next, thanks to a ... to trolling for weaker, soft-bodied animals you stumble upon ... giant pterygotid eurypterid, the largest arthropod that ever lived. ... journal Biology Letters , dramatically re-interprets the creature,s ...
(Date:7/10/2014)... The controversy centres around a family of enzymes known ... heme group in their active site. At the centre ... which becomes oxidised (ferryl) when a reacting heme is ... that has remained unanswered for decades is whether this ... hydroxyl group (OH). Resolving this fundamental question has implications ...
(Date:7/10/2014)... research from The University of Texas Health Science Center ... Real (IYG), a health education program designed to delay ... reduce dating violence behaviors among minority youth. , According ... percent of high school youth are victims of physical ... 20 percent are victims of emotional dating violence. Previous ...
Breaking Biology News(10 mins):Extinct sea scorpion gets a Yale eye exam, with surprising results 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... Brian Chen has been awarded a prestigious Sloan Research ... Formation, investigates a big subject: deciphering the assembly instructions ... neural circuits wire up with precision. One of the ... the correct synaptic contacts during its development when faced ...
... named Brontomerus mcintoshi , or "thunder-thighs" after its enormously powerful ... is described in a paper recently published in the journal ... the U.K. and the U.S. A member of the ... Brachiosaurus , Brontomerus may have used its powerful ...
... the crowd? Is that all I,ll ever be? ... Do you ... the Crowd" It may seem paradoxical, but being ... UCLA life scientists. Biologists Kimberly Pollard and Daniel ... alarm-call vocalizations in eight species of rodents that live in social ...
Cached Biology News:Prestigious Sloan Fellowship awarded 2New 'thunder-thighs' dinosaur discovered 2New 'thunder-thighs' dinosaur discovered 3Even in a crowd, you remain unique, UCLA life scientists report 2
...
...
... The T7 Phage Capture Plate is a 96-well ... which the T7 Tail Fiber Monoclonal Antibody is ... activity. The antibody specifically recognizes the tail fiber ... plate has a capacity of 10 9 ...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
Biology Products: